A Comprehensive Essay Part 2 In Part 1 of our comprehensive essay series Vertex Pharmaceuticals (VRTX) …

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement …

A Comprehensive Essay Part 1 Yes, we have stories to tell about some of our picked …

Prohost Letter #438 End of the Year Issue  2019 Happy New Year 2020 The NASDAQ reached …

Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, …

More from the Prohost Portfolio with Our Observations Gilead (GILD) has cash and new products reaching …

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, …

Exelixis Positive Results from IMspire 150 Exelixis (EXEL) announced positive results from IMspire 150; the phase 3 …

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at …

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks Forty-Seven (FTSV) and  IVERIC bio …